RxDoctor Payments Data

Crystal Threadgill

Psychiatric/Mental Health · Mobile, ALNPI 1528500907

Payments from drug & device makers

$2,729in general payments, 2019–2025

Across 162 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alkermes, Inc.$303
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$289
  • Otsuka America Pharmaceutical, Inc.$173
  • Johnson & Johnson$134
  • Lundbeck LLC$101
  • plus $456 from 13 others

What the payments were for

  • Food & beverage$2,729100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,729 in reported general payments places this provider in the 70th percentile of 378 psychiatric/mental health providers in Alabama.

See all psychiatric/mental health providers in Alabama

Medicare billing

Part B allowed, 2024
$9,704
Medicare patients
18
Services billed
127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole32$63,815
VraylarCariprazine Hcl13$20,008
TrintellixVortioxetine Hydrobromide26$15,816
Lurasidone Hcl36$7,459
Buspirone Hcl140$3,560
Trazodone Hcl108$3,038
Vilazodone Hcl23$2,517
Divalproex Sodium ErDivalproex Sodium31$2,178
Venlafaxine Hcl ErVenlafaxine Hcl53$1,644
Aripiprazole62$1,285
Atomoxetine Hcl13$1,144
Risperidone79$1,078
Hydroxyzine Hcl64$959
Bupropion XlBupropion Hcl39$869
Divalproex Sodium40$864

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$173$63,81532 claims
AbbVieVraylar$1,273$20,00813 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$95$15,81626 claims
Almatica Pharma LLCSertraline Hcl$21$43752 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 378 psychiatric/mental health providers in Alabama.

Other psychiatric/mental health in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →